Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors

Sung Hee Hwang, Aaron T. Wecksler, Guodong Zhang, Christophe Morisseau, Long V. Nguyen, Samuel H. Fu, Bruce D. Hammock

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


To reduce the pro-angiogenic effects of sEH inhibition, a structure-activity relationship (SAR) study was performed by incorporating structural features of the anti-angiogenic multi-kinase inhibitor sorafenib into soluble epoxide hydrolase (sEH) inhibitors. The structural modifications of this series of molecules enabled the altering of selectivity towards the pro-angiogenic kinases C-RAF and vascular endothelial growth factor receptor-2 (VEGFR-2), while retaining their sEH inhibition. As a result, sEH inhibitors with greater potency against C-RAF and VEGFR-2 were obtained. Compound 4 (t-CUPM) possesses inhibition potency higher than sorafenib towards sEH but similar against C-RAF and VEGFR-2. Compound 7 (t-CUCB) selectively inhibits sEH, while inhibiting HUVEC cell proliferation, a potential anti-angiogenic property, without liver cancer cell cytotoxicity. The data presented suggest a potential rational approach to control the angiogenic responses stemming from sEH inhibition.

Original languageEnglish (US)
Pages (from-to)3732-3737
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Issue number13
StatePublished - Jul 1 2013


  • Angiogenesis
  • C-RAF kinase
  • Regorafenib
  • Soluble epoxide hydrolase (sEH)
  • Sorafenib
  • VEGFR-2

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry


Dive into the research topics of 'Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors'. Together they form a unique fingerprint.

Cite this